Human tissue kallikreins as prognostic biomarkers and as potential targets for anticancer therapy

Wun Shaing W. Chang, Ruey Hwang Chou, Cheng Wen Wu, Jang-Yang Chang

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

The tissue kallikrein family represents the largest cluster of contiguous proteinase genes in the entire human genome. Its 15 members are expressed primarily in a tissue-specific manner, but can also be detected in biological fluids such as serum and seminal plasma. The mature active tissue kallikreins play vital roles in numerous physiological and pathological processes, in which they are able to function individually or in cascade pathway(s). Their genetic polymorphisms, alternative splicings and aberrant amounts of transcripts and/or proteins are often correlated with increased cancer risk, thus providing a sensible application for the use of tissue kallikreins as diagnostic, prognostic and predictive tumour markers. In this review, an updated overview of scientific research and patents regarding the functional features and clinical indications of tissue kallikreins in neoplastic diseases is provided.

Original languageEnglish
Pages (from-to)1227-1240
Number of pages14
JournalExpert Opinion on Therapeutic Patents
Volume17
Issue number10
DOIs
Publication statusPublished - 2007 Oct 1

Fingerprint

Tissue Kallikreins
Biomarkers
Physiological Phenomena
Patents
Alternative Splicing
Genetic Polymorphisms
Human Genome
Pathologic Processes
Therapeutics
Tumor Biomarkers
Semen
Peptide Hydrolases
Serum
Research
Genes
Neoplasms
Proteins

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery

Cite this

Chang, Wun Shaing W. ; Chou, Ruey Hwang ; Wu, Cheng Wen ; Chang, Jang-Yang. / Human tissue kallikreins as prognostic biomarkers and as potential targets for anticancer therapy. In: Expert Opinion on Therapeutic Patents. 2007 ; Vol. 17, No. 10. pp. 1227-1240.
@article{1365136088984ae38f46f19f2a6d8205,
title = "Human tissue kallikreins as prognostic biomarkers and as potential targets for anticancer therapy",
abstract = "The tissue kallikrein family represents the largest cluster of contiguous proteinase genes in the entire human genome. Its 15 members are expressed primarily in a tissue-specific manner, but can also be detected in biological fluids such as serum and seminal plasma. The mature active tissue kallikreins play vital roles in numerous physiological and pathological processes, in which they are able to function individually or in cascade pathway(s). Their genetic polymorphisms, alternative splicings and aberrant amounts of transcripts and/or proteins are often correlated with increased cancer risk, thus providing a sensible application for the use of tissue kallikreins as diagnostic, prognostic and predictive tumour markers. In this review, an updated overview of scientific research and patents regarding the functional features and clinical indications of tissue kallikreins in neoplastic diseases is provided.",
author = "Chang, {Wun Shaing W.} and Chou, {Ruey Hwang} and Wu, {Cheng Wen} and Jang-Yang Chang",
year = "2007",
month = "10",
day = "1",
doi = "10.1517/13543776.17.10.1227",
language = "English",
volume = "17",
pages = "1227--1240",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Informa Healthcare",
number = "10",

}

Human tissue kallikreins as prognostic biomarkers and as potential targets for anticancer therapy. / Chang, Wun Shaing W.; Chou, Ruey Hwang; Wu, Cheng Wen; Chang, Jang-Yang.

In: Expert Opinion on Therapeutic Patents, Vol. 17, No. 10, 01.10.2007, p. 1227-1240.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Human tissue kallikreins as prognostic biomarkers and as potential targets for anticancer therapy

AU - Chang, Wun Shaing W.

AU - Chou, Ruey Hwang

AU - Wu, Cheng Wen

AU - Chang, Jang-Yang

PY - 2007/10/1

Y1 - 2007/10/1

N2 - The tissue kallikrein family represents the largest cluster of contiguous proteinase genes in the entire human genome. Its 15 members are expressed primarily in a tissue-specific manner, but can also be detected in biological fluids such as serum and seminal plasma. The mature active tissue kallikreins play vital roles in numerous physiological and pathological processes, in which they are able to function individually or in cascade pathway(s). Their genetic polymorphisms, alternative splicings and aberrant amounts of transcripts and/or proteins are often correlated with increased cancer risk, thus providing a sensible application for the use of tissue kallikreins as diagnostic, prognostic and predictive tumour markers. In this review, an updated overview of scientific research and patents regarding the functional features and clinical indications of tissue kallikreins in neoplastic diseases is provided.

AB - The tissue kallikrein family represents the largest cluster of contiguous proteinase genes in the entire human genome. Its 15 members are expressed primarily in a tissue-specific manner, but can also be detected in biological fluids such as serum and seminal plasma. The mature active tissue kallikreins play vital roles in numerous physiological and pathological processes, in which they are able to function individually or in cascade pathway(s). Their genetic polymorphisms, alternative splicings and aberrant amounts of transcripts and/or proteins are often correlated with increased cancer risk, thus providing a sensible application for the use of tissue kallikreins as diagnostic, prognostic and predictive tumour markers. In this review, an updated overview of scientific research and patents regarding the functional features and clinical indications of tissue kallikreins in neoplastic diseases is provided.

UR - http://www.scopus.com/inward/record.url?scp=36148991024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36148991024&partnerID=8YFLogxK

U2 - 10.1517/13543776.17.10.1227

DO - 10.1517/13543776.17.10.1227

M3 - Review article

VL - 17

SP - 1227

EP - 1240

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 10

ER -